Becton Dickinson, one of the world’s largest medical technology companies, said in a statement Tuesday it has entered into a definitive agreement to sell its surgical instrumentation platform to Steris, an Ohio-based medical device firm specializing in infection prevention.
The sale includes BD’s V. Mueller, Snowden-Pencer and Genesis brands as well as three manufacturing facilities in St. Louis, Cleveland, and Tuttlingen, Germany. Some 360 employees will transfer to Steris when the deal closes by the end of September.
BD’s surgical instrumentation platform is part of the company’s interventional business segment.
In a statement, New Jersey-based BD said selling the platform “advances the ‘Simplify’ pillar” of the firm’s strategy to slim its product portfolio and manufacturing network.
The transaction is significant for Steris, which employs 17,000 people worldwide. The company had global sales of $4.96 billion and a net loss of $27.9 million in its most recent fiscal year.
Needham analysts led by Mike Matson applauded the transaction. READ MORE
By Peter Green
Source: medtechdive.com
AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey. The leading data and analytics company’s report, “The State of the Biopharmaceutical Industry – 2025,” highlights AI’s potential to boost productivity and cut costs in the coming year.
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as atopic dermatitis, asthma, and COPD.
While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as the first closed-loop therapy approach—allowing for self-adjusting neuromodulation in real time to help control the condition’s motor symptoms.
